Trial · NCT01857310
Results by group130
Each measurement the trial posted, group by group, in the words and numbers it posted.
81 to 100 of 130
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Neonatal Mortality | Folic Acid and Zinc Supplementation | 3 | Participants | ||
| Neonatal Mortality | Placebo | 2 | Participants | ||
| Major Neonatal Complications | Folic Acid and Zinc Supplementation | 2 | Participants | ||
| Major Neonatal Complications | Placebo | 1 | Participants | ||
| Structural Malformations | Folic Acid and Zinc Supplementation | 15 | Participants | ||
| Structural Malformations | Placebo | 14 | Participants | ||
| Severe Maternal Morbidity | Folic Acid and Zinc Supplementation | 15 | Participants | ||
| Severe Maternal Morbidity | Placebo | 10 | Participants | ||
| Fertilization Rate Per Cycle, % | Folic Acid and Zinc Supplementation | 75.3 | Standard Deviation 2.25 | percent per cycle | |
| Fertilization Rate Per Cycle, % | Placebo | 77.7 | Standard Deviation 1.74 | percent per cycle | |
| Number of Good Quality Embryos on Day 5 Per Cycle | Folic Acid and Zinc Supplementation | 2.66 | Standard Deviation 0.23 | embryos per cycle | |
| Number of Good Quality Embryos on Day 5 Per Cycle | Placebo | 2.98 | Standard Deviation 0.21 | embryos per cycle | |
| Percentage of Good Quality Embryos on Day 5 Per Cycle | Folic Acid and Zinc Supplementation | 17.2 | Standard Deviation 2.05 | percent per cycle | |
| Percentage of Good Quality Embryos on Day 5 Per Cycle | Placebo | 18.5 | Standard Deviation 1.81 | percent per cycle | |
| Number of Embryos Transferred Per Cycle | Folic Acid and Zinc Supplementation | 1.50 | Standard Deviation 0.06 | embryos per cycle | |
| Number of Embryos Transferred Per Cycle | Placebo | 1.51 | Standard Deviation 0.05 | embryos per cycle | |
| Number of Embryos Cryopreserved Per Cycle | Folic Acid and Zinc Supplementation | 4.22 | Standard Deviation 0.32 | embryos per cycle | |
| Number of Embryos Cryopreserved Per Cycle | Placebo | 4.32 | Standard Deviation 0.31 | embryos per cycle | |
| Sperm Penetration Per Cycle, % | Folic Acid and Zinc Supplementation | 62.7 | Standard Deviation 13.0 | percent penetration | |
| Sperm Penetration Per Cycle, % | Placebo | 74.8 | Standard Deviation 11.0 | percent penetration |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01857310/results?page=5